Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer

Aaron Mansfield, A. J. Tafur, C. E. Wang, Taxiarchis Kourelis, E. M. Wysokinska, Ping Yang

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Essentials Venous thromboembolism (VTE) prevention strategies require effective risk assessment models. We sought to validate the Khorana Risk Score (KRS) in patients with lung cancer. A high KRS was not predictive of VTE but was independently associated with all-cause mortality. Our findings stress the need for a lung cancer-specific VTE risk assessment model. Summary: Objectives Lung cancer is strongly associated with venous thromboembolism (VTE), but primary prevention against VTE is not a validated management strategy. Risk assessment models will be necessary for efficient implementation of preventative strategies. Materials and methods Utilizing a prospectively collected lung cancer database, we aimed to validate the Khorana Risk Score (KRS) in the prediction of VTE among patients with lung cancer. VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risk models. Mortality prediction was evaluated as a secondary outcome. Results We included 719 patients in our review. The patients were predominantly older men with non-small cell lung cancer and 40% had metastatic disease at inception. The median follow-up was 15.2 months. There were 83 VTEs (11.5%) and 568 (78.8%) patients died. A high KRS (cumulative incidence, 12.4%; 95% confidence interval [CI], 6.4–20.5%) was not associated with VTE compared with an intermediate score (cumulative incidence, 12.1%; 95% confidence interval, 9.5–15.0%) in both univariate and multivariable analyses. However, a high KRS was a predictor of mortality (hazard ratio, 1.7; 95% CI, 1.4–2.2). Conclusions Among patients with lung cancer, the KRS did not stratify the patients at the highest risk of VTE. Improved risk stratification methods are needed for this group of patients prior to implementing a primary prevention strategy.

Original languageEnglish (US)
Pages (from-to)1773-1778
Number of pages6
JournalJournal of Thrombosis and Haemostasis
Volume14
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Venous Thromboembolism
Lung Neoplasms
Neoplasms
Confidence Intervals
Primary Prevention
Mortality
Incidence
Non-Small Cell Lung Carcinoma
Databases

Keywords

  • lung cancer
  • mortality
  • prediction score
  • prevention
  • venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Predictors of active cancer thromboembolic outcomes : validation of the Khorana score among patients with lung cancer. / Mansfield, Aaron; Tafur, A. J.; Wang, C. E.; Kourelis, Taxiarchis; Wysokinska, E. M.; Yang, Ping.

In: Journal of Thrombosis and Haemostasis, Vol. 14, No. 9, 01.09.2016, p. 1773-1778.

Research output: Contribution to journalArticle

@article{bbd16db41b7b498b9f93dfdbc5ac1954,
title = "Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer",
abstract = "Essentials Venous thromboembolism (VTE) prevention strategies require effective risk assessment models. We sought to validate the Khorana Risk Score (KRS) in patients with lung cancer. A high KRS was not predictive of VTE but was independently associated with all-cause mortality. Our findings stress the need for a lung cancer-specific VTE risk assessment model. Summary: Objectives Lung cancer is strongly associated with venous thromboembolism (VTE), but primary prevention against VTE is not a validated management strategy. Risk assessment models will be necessary for efficient implementation of preventative strategies. Materials and methods Utilizing a prospectively collected lung cancer database, we aimed to validate the Khorana Risk Score (KRS) in the prediction of VTE among patients with lung cancer. VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risk models. Mortality prediction was evaluated as a secondary outcome. Results We included 719 patients in our review. The patients were predominantly older men with non-small cell lung cancer and 40{\%} had metastatic disease at inception. The median follow-up was 15.2 months. There were 83 VTEs (11.5{\%}) and 568 (78.8{\%}) patients died. A high KRS (cumulative incidence, 12.4{\%}; 95{\%} confidence interval [CI], 6.4–20.5{\%}) was not associated with VTE compared with an intermediate score (cumulative incidence, 12.1{\%}; 95{\%} confidence interval, 9.5–15.0{\%}) in both univariate and multivariable analyses. However, a high KRS was a predictor of mortality (hazard ratio, 1.7; 95{\%} CI, 1.4–2.2). Conclusions Among patients with lung cancer, the KRS did not stratify the patients at the highest risk of VTE. Improved risk stratification methods are needed for this group of patients prior to implementing a primary prevention strategy.",
keywords = "lung cancer, mortality, prediction score, prevention, venous thromboembolism",
author = "Aaron Mansfield and Tafur, {A. J.} and Wang, {C. E.} and Taxiarchis Kourelis and Wysokinska, {E. M.} and Ping Yang",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/jth.13378",
language = "English (US)",
volume = "14",
pages = "1773--1778",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Predictors of active cancer thromboembolic outcomes

T2 - validation of the Khorana score among patients with lung cancer

AU - Mansfield, Aaron

AU - Tafur, A. J.

AU - Wang, C. E.

AU - Kourelis, Taxiarchis

AU - Wysokinska, E. M.

AU - Yang, Ping

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Essentials Venous thromboembolism (VTE) prevention strategies require effective risk assessment models. We sought to validate the Khorana Risk Score (KRS) in patients with lung cancer. A high KRS was not predictive of VTE but was independently associated with all-cause mortality. Our findings stress the need for a lung cancer-specific VTE risk assessment model. Summary: Objectives Lung cancer is strongly associated with venous thromboembolism (VTE), but primary prevention against VTE is not a validated management strategy. Risk assessment models will be necessary for efficient implementation of preventative strategies. Materials and methods Utilizing a prospectively collected lung cancer database, we aimed to validate the Khorana Risk Score (KRS) in the prediction of VTE among patients with lung cancer. VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risk models. Mortality prediction was evaluated as a secondary outcome. Results We included 719 patients in our review. The patients were predominantly older men with non-small cell lung cancer and 40% had metastatic disease at inception. The median follow-up was 15.2 months. There were 83 VTEs (11.5%) and 568 (78.8%) patients died. A high KRS (cumulative incidence, 12.4%; 95% confidence interval [CI], 6.4–20.5%) was not associated with VTE compared with an intermediate score (cumulative incidence, 12.1%; 95% confidence interval, 9.5–15.0%) in both univariate and multivariable analyses. However, a high KRS was a predictor of mortality (hazard ratio, 1.7; 95% CI, 1.4–2.2). Conclusions Among patients with lung cancer, the KRS did not stratify the patients at the highest risk of VTE. Improved risk stratification methods are needed for this group of patients prior to implementing a primary prevention strategy.

AB - Essentials Venous thromboembolism (VTE) prevention strategies require effective risk assessment models. We sought to validate the Khorana Risk Score (KRS) in patients with lung cancer. A high KRS was not predictive of VTE but was independently associated with all-cause mortality. Our findings stress the need for a lung cancer-specific VTE risk assessment model. Summary: Objectives Lung cancer is strongly associated with venous thromboembolism (VTE), but primary prevention against VTE is not a validated management strategy. Risk assessment models will be necessary for efficient implementation of preventative strategies. Materials and methods Utilizing a prospectively collected lung cancer database, we aimed to validate the Khorana Risk Score (KRS) in the prediction of VTE among patients with lung cancer. VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risk models. Mortality prediction was evaluated as a secondary outcome. Results We included 719 patients in our review. The patients were predominantly older men with non-small cell lung cancer and 40% had metastatic disease at inception. The median follow-up was 15.2 months. There were 83 VTEs (11.5%) and 568 (78.8%) patients died. A high KRS (cumulative incidence, 12.4%; 95% confidence interval [CI], 6.4–20.5%) was not associated with VTE compared with an intermediate score (cumulative incidence, 12.1%; 95% confidence interval, 9.5–15.0%) in both univariate and multivariable analyses. However, a high KRS was a predictor of mortality (hazard ratio, 1.7; 95% CI, 1.4–2.2). Conclusions Among patients with lung cancer, the KRS did not stratify the patients at the highest risk of VTE. Improved risk stratification methods are needed for this group of patients prior to implementing a primary prevention strategy.

KW - lung cancer

KW - mortality

KW - prediction score

KW - prevention

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84988487444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988487444&partnerID=8YFLogxK

U2 - 10.1111/jth.13378

DO - 10.1111/jth.13378

M3 - Article

C2 - 27273134

AN - SCOPUS:84988487444

VL - 14

SP - 1773

EP - 1778

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 9

ER -